The nuclear expression of the small heat shock protein – alpha B crystalline as a marker for poor prognosis in NSCLC patients Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Expression of claudins 1, 2, 3, 4, 5 and 7 in lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
TGF-beta-dependent inhibitor of DNA protein (Id) expression in lung fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 521s Year: 2006
Accuracy of EGFR and K-Ras mutation detection in non small cell lung carcinoma: Ring trial in 15 molecular French laboratories (ERMETIC project – Part 1) Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Expression of D2-40 in small cell lung carcinomas (SCLC); Association with lymphatic invasion(L.I), clinical parameters and prognosis Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer Year: 2010
Human prohibitin 1 (hPH1) protein overexpression in COPD: preliminary results Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009
EGFR and hTERT mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implicationsSource: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Expression of transforming growth factors beta (1, 2, 3) and connective tissue growth factor in the peripheral lung from GOLD stage 1-2 COPD patients and smokers with normal lung function Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Late-breaking abstract: Relationship of aquaporin 1, 3 and 5 expression in lung cancer cells to cellular differentiation, invasive growth and metastasis potential Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005
Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015
The effect of post operative physical training on activity after curative surgery for non small cell lung cancer (NSCLC) – RCT Source: Annual Congress 2012 - The best abstracts in pulmonary rehabilitation Year: 2012
Expression of claudins 1, 2, 3, 4, 5 and 7 in usual interstitial pneumonia and sarcoidosis Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
The NANCI lncRNA-NKX2-1 gene duplex impacts prognosis in stage I NSCLC. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
EGFR and hTERT expression in high risk COPD patients – clinical application Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011